Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Qualigen Therapeutics Inc (QLGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/02/2025: QLGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.72% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.51M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 0.03 | 52 Weeks Range 2.85 - 29.43 | Updated Date 07/1/2025 |
52 Weeks Range 2.85 - 29.43 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -17.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-06-30 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -126.39% | Return on Equity (TTM) -841.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3559518 | Price to Sales(TTM) 0.39 |
Enterprise Value 3559518 | Price to Sales(TTM) 0.39 | ||
Enterprise Value to Revenue 0.68 | Enterprise Value to EBITDA -0.05 | Shares Outstanding 736431 | Shares Floating 735989 |
Shares Outstanding 736431 | Shares Floating 735989 | ||
Percent Insiders 3.77 | Percent Institutions 1.17 |
Analyst Ratings
Rating 1 | Target Price 5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Qualigen Therapeutics Inc
Company Overview
History and Background
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for cancer and infectious diseases. Founded in 2011, it has transitioned through various stages of development, focusing on its core technology platforms and pipeline of drug candidates.
Core Business Areas
- Oncology Therapeutics: Development of small molecule therapeutics targeting cancer, including QN-302, a G-quadruplex selective transcription inhibitor.
- Infectious Diseases Therapeutics: Developing ALVR112, a therapeutic for the treatment of COVID-19 and other viral infectious diseases.
Leadership and Structure
The leadership team consists of a CEO, CFO, and other key executives responsible for driving the company's strategy and operations. The organizational structure is typical of a biotechnology company, with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- QN-302: A small molecule G-quadruplex selective transcription inhibitor being developed for cancer treatment. It's in preclinical development. Market share data is not currently available as the product is not yet commercialized. Competitors: Other companies developing G-quadruplex targeting drugs or similar cancer therapies.
- ALVR112: A direct-acting antiviral therapeutic candidate for the treatment of COVID-19 and other viral diseases. It's in preclinical development. Market share data is not currently available as the product is not yet commercialized. Competitors: Other companies developing antiviral drugs for COVID-19, such as Pfizer (PFE) and Merck (MRK).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk, high reward, and intense competition. Advances in genomics, proteomics, and personalized medicine are driving innovation, but regulatory hurdles and lengthy development timelines pose significant challenges.
Positioning
Qualigen Therapeutics Inc. is a relatively small player in the biotechnology industry, focusing on specific therapeutic areas. Its competitive advantage lies in its proprietary technology platforms and targeted approach to drug development.
Total Addressable Market (TAM)
The oncology and antiviral therapeutics markets are substantial, with billions of dollars in potential revenue. Qualigen's positioning within these markets is dependent on the successful development and commercialization of its drug candidates. Expected oncology TAM is approximately $200 billion (USD) by 2027, and antiviral TAM is also substantial, depending on emerging viruses.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms (G-quadruplex targeting, ALVR112)
- Targeted approach to drug development
- Potential for breakthrough therapies in unmet medical needs
Weaknesses
- Limited financial resources
- Early-stage development pipeline
- Dependence on successful clinical trials
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion of pipeline through acquisitions or licensing
- Government funding and grants
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent infringement challenges
- Funding constraints and market volatility
Competitors and Market Share
Key Competitors
- PFE
- MRK
- LLY
- JNJ
- BMY
Competitive Landscape
Qualigen Therapeutics Inc. faces intense competition from larger pharmaceutical companies with greater financial and R&D resources. Its competitive advantage lies in its proprietary technology and targeted approach, but it must overcome significant hurdles to successfully commercialize its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited by the company's focus on R&D. Growth potential is tied to successful clinical trials and subsequent commercialization of its drug candidates.
Future Projections: Future projections are highly uncertain and dependent on clinical trial outcomes. Analyst estimates vary widely based on the perceived probability of success for the company's drug candidates.
Recent Initiatives: Recent initiatives include advancing QN-302 and ALVR112 through preclinical and clinical development, seeking partnerships and collaborations, and exploring potential acquisitions to expand its pipeline.
Summary
Qualigen Therapeutics is a high-risk, high-reward biotechnology company focused on developing innovative cancer and infectious disease therapeutics. Its success hinges on the successful clinical development and commercialization of its pipeline assets. The company's limited financial resources and dependence on positive trial outcomes pose significant challenges, while potential partnerships and expansion opportunities could drive future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Third-party financial data providers
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qualigen Therapeutics Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2015-06-24 | Interim CEO, Interim CFO & Chairman of the Board Mr. Kevin A. Richardson II | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.qlgntx.com |
Full time employees 4 | Website https://www.qlgntx.com | ||
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1 clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS for the treatment of advanced solid tumors. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.